Why did MSB fall 11.1% on 19 Oct 2026?

MSB

Mesoblast · Pharmaceuticals, Biotechnology & Life Sciences

▼ 11.1%at the close on Mon 19 Oct

$10,000 in MSB shares fell to $8,894 that day. It was down as much as 11.8% during the day: about 5 times a usual day's move for MSB, with twice the usual shares traded.

Results worse than analysts expected

Mesoblast fell sharply after releasing quarterly results showing Ryoncil revenue growth that disappointed investors relative to expectations, triggering a 'sell the news' reaction despite headline growth figures.

$10,000 in ISO, the ETF that holds the most MSB, lost ▼ $9 that day. In IOZ it was a loss of $1. 17 ETFs hold MSB ›

An ETF is one investment, bought on the stock exchange, that holds many companies at once.

The news

10 of the 10 articles we read name Mesoblast. Headlines link to the publisher.

The other 8 articles ›
How the model got there ›

Multiple news headlines published around the detection date explicitly ask 'Why Did Mesoblast Fall Despite Strong Ryoncil Growth?' and 'What Disappointed Investors?', indicating a results release where headline revenue growth was present but fell short of market expectations. The same-industry peers' median move was only -1.96% across 45 peers, and the ASX Health sector index (^AXHJ) was up +4.21%, ruling out sector_flow or broad industry pressure as the cause — this is clearly stock-specific. The -11.06% close on 1.5x normal volume is consistent with a disappointing financial update rather than a routine market move, and no ASX announcement was captured likely due to the 18-hour window cutoff, with the results appearing to have landed just outside it.

Markets that moved with it · 1

Markets that tend to move with this stock, on the same day or the day before.

  • ASX 200 Health CareIts sector · same dayother way+0.04%

What $10,000 in each ETF lost that day

$77 of every $10,000 in ISO was Mesoblast; it fell 11.1%, so $10,000 in ISO lost $9.

9 more ETFs ›

How is the site working for you?